Drug intelligence / Profile preview

Rhea-004

Development stage: Preclinical
Lead developer: Rhea Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal

Overview

Rhea-004 is a small molecule pan-coronavirus therapeutic being developed by Rhea Pharmaceuticals. Currently in the discovery phase, it is being explored as an intranasal nasal spray designed to prevent the progression and transmission of various beta-coronaviruses, including SARS-CoV-2 and those responsible for the common cold. The drug's specific molecular target has not been disclosed, as it is an anti-infective agent targeting the pathogen rather than a human molecular target.

Beyond the preview

Go deeper on Rhea-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhea-004.

Explore the full profile